Cargando…

Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review

Multiple sclerosis (MS) is a chronic systemic autoimmune disorder characterized by plaques of demyelination, autoimmune inflammation, and astrocytic gliosis. The primary cells involved in the pathophysiology of MS are T cells. However, B cells have recently been implicated in the pathophysiology of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azhar, Ayesha, Taimuri, Muskan Asim, Shamat, Shamat Fathi, Ikram, Areeba, Ali, Sajjad, Ali, Tehreem, Khabir, Yumna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553037/ https://www.ncbi.nlm.nih.gov/pubmed/37811115 http://dx.doi.org/10.1097/MS9.0000000000001184

Ejemplares similares

Are female adolescents in low and middle-income countries prepared for menarche?
por: Taimuri, Muskan Asim, et al.
Publicado: (2022)

Re-emergence of vaccine-derived poliovirus in Israel, US, and UK – Call for promoting the use of novel oral polio vaccine
por: Shahnoor, Syeda, et al.
Publicado: (2022)

Profile of Some Trace Elements in the Liver of Camels, Sheep, and Goats in the Sudan
por: Ibrahim, Ibrahim Abdullah, et al.
Publicado: (2013)

Nirogacestat and its potential impact on desmoid tumor
por: Rohail, Samia, et al.
Publicado: (2023)

Implementing Infant and Young Child Feeding in Emergencies during COVID-19 in Primary Healthcare Facilities in Syria
por: El-Kour, T., et al.
Publicado: (2021)

A rare multiple myeloma complication as a spinal cord metastasis: A case report
por: Mansour, Marah, et al.
Publicado: (2023)

FlexBurst360 therapy – A new spine cord stimulation system (SCS) for patients with chronic pain
por: Khabir, Yumna, et al.
Publicado: (2022)

Rapid-acting oral drug (Auvelity) for major depressive disorder
por: Khabir, Yumna, et al.
Publicado: (2022)

Zynteglo: Betibeglogene autotemcel – An innovative therapy for β- thalassemia patients
por: Asghar, Adam Ali, et al.
Publicado: (2022)

Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse
por: Mills, Elizabeth A., et al.
Publicado: (2017)

Effect of Air Pollutant Markers on Multiple Sclerosis Relapses
por: Mehrpour, Masoud, et al.
Publicado: (2013)

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy
por: Castillo-Trivino, Tamara, et al.
Publicado: (2011)

Kyzatrex - Oral testosterone replacement therapy
por: Asghar, Adam Ali, et al.
Publicado: (2022)

Internet addiction and sleep quality among medical students during the COVID-19 pandemic: A multinational cross-sectional survey
por: Tahir, Muhammad Junaid, et al.
Publicado: (2021)

Development and Validation of Fear of Relapse Scale for Relapsing-Remitting Multiple Sclerosis: Understanding Stressors in Patients
por: Khatibi, Ali, et al.
Publicado: (2020)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Monkeypox outbreak amidst COVID-19 reemergence in the European Region: Challenges, efforts, and recommendations
por: Zaheer, Amna Binte, et al.
Publicado: (2022)

Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse
por: McKay, Kyla A., et al.
Publicado: (2022)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Seasonal variation in multiple sclerosis relapse
por: Harding, Katharine, et al.
Publicado: (2017)

Factors Involved in Relapse of Multiple Sclerosis
por: Kamel, Fatemah Omar
Publicado: (2019)

Osteopontin Is Associated with Multiple Sclerosis Relapses
por: Stampanoni Bassi, Mario, et al.
Publicado: (2023)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

The application of extended reality in cardiac surgery: potential implications for low- and middle-income countries
por: Khabir, Yumna, et al.
Publicado: (2023)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
por: Imani, Ali, et al.
Publicado: (2012)

Jacksonian seizure as the relapse symptom of multiple sclerosis
por: Najafi, Mohammad Reza, et al.
Publicado: (2013)

Lymphopenia in treatment-naive relapsing multiple sclerosis
por: Lim, Zhi Wei, et al.
Publicado: (2016)

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses
por: Ramo-Tello, Cristina, et al.
Publicado: (2021)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Predictors of severity and outcome of multiple sclerosis relapses
por: Hosny, Hassan Saad, et al.
Publicado: (2023)

The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care
por: Asano, Miho, et al.
Publicado: (2015)

FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology
por: Sheikh, Ayesha, et al.
Publicado: (2022)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

How to run a multiple sclerosis relapse clinic
por: Tallantyre, Emma C, et al.
Publicado: (2016)

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
por: Kang, Connie, et al.
Publicado: (2021)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0ci0e5kgb6ss4cj1dba7i7bm4g